



thetrutides

KLOW BLEND

BPC-157 + TB-500 + KPV + GHK-Cu — the four-peptide formulation

UPDATED 4 AUGUST 2026

KLOW is the broadest formulation in the range, adding an anti-inflammatory tripeptide to the GLOW base. Three of its four components were recommended by the FDA advisory committee in July 2026; the fourth has not been reviewed yet.

● In Plain English

KLOW bundles four peptides that each target a different part of the repair process: a general repair signal, a tissue-migration signal, an inflammation damper and a copper-carrying skin and collagen peptide. It is the most comprehensive formulation in the range and, for the same reason, the hardest to attribute results to any single component.

What people use it for. The broadest coverage option — repair, inflammation and skin all in one preparation. People generally choose it when they want one vial to cover several bases rather than running multiple products.

What to know before you buy. The trade-off with four actives is that if something works, or something bothers you, you will have no way of knowing which component did it. If figuring that out matters to you, single compounds answer that question and blends cannot. KLOW also fully overlaps with Wolverine and largely overlaps with GLOW, so these should be alternatives to one another rather than additions.

● What It's Used For

GOAL	WHAT THAT RESTS ON
All-round repair	Four peptides covering repair signalling, inflammation and skin in one preparation
Inflammation	KPV, the anti-inflammatory fragment of α -MSH
Skin and collagen	GHK-Cu, the best-evidenced component in the range
Simplicity	Replaces running three or four separate products

The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.



● Pricing & Sizes

PRICING

80mg vial

\$110

Bulk pricing: 2-3 vials -5% | 4-6 vials -10% | 7-9 vials -15% | 10+ vials -20%

Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

Reconstitution — bacteriostatic water: 80mg vial at 3mL = 26.7mg/mL, so 10 units on a 100-unit syringe draws 2.67mg. Concentrations are arithmetic from vial content and diluent volume, not a dosing recommendation.

Bought separately, GHK-Cu 50mg (\$35) plus BPC-157 10mg (\$48) is **\$83**. KLOW is **\$110**, so 10mg of TB-500 and 10mg of KPV together cost **\$27**. Neither is sold as a standalone vial.

● At a Glance

COMPONENTS	BPC-157, TB-500, KPV and GHK-Cu
TYPICAL RATIO	GHK-Cu 50mg / BPC-157 10mg / TB-500 10mg / KPV 10mg
RATIONALE	Repair signalling, anti-inflammatory action and skin or connective tissue support in a single preparation
REGULATORY (US)	No component is FDA-approved. BPC-157, TB-500 and KPV were each recommended 8-6-1 for 503A listing on 23 July 2026; no FDA action since
GHK-CU TRACK	Not on the July agenda; separate PCAC meeting expected before end of February 2027
FORMAT	80mg vial

4

ACTIVE PEPTIDES

3 of 4

RECOMMENDED IN JULY

8-6-1

VOTE ON EACH

0

STUDIES OF THE BLEND

REGULATORY STATUS — READ THIS FIRST

Three components — BPC-157, TB-500 and KPV — were each recommended **8-6-1** for the 503A bulks list on 23 July 2026. That vote is **advisory only**. As of 4 August 2026 the FDA has taken no action on it, has not opened rulemaking, and has not moved the substance to the interim Category 1 list. FDA's own scientific reviewers had recommended *against* all seven peptides; the committee voted against staff on six consecutive votes, so the usual assumption that a PCAC recommendation predicts the agency's decision is weaker here than normal. **GHK-Cu was not reviewed** and remains on a separate track expected before the end of February 2027. Several outlets have reported this as the FDA "clearing", "approving" or "adding" these peptides to the bulks list. That is inaccurate. Nothing has been added and nothing is legally cleared.

● How the Components Compare

Each component brings something the others do not — and each has gaps the others fill. This is what is actually in the vial, stated plainly:

COMPONENT	WHAT IT ADDS	WHAT IT DOES NOT DO
GHK-Cu	Best-evidenced of the four. Collagen, skin firmness, hair — the cosmetic layer none of the others cover	Evidence is largely topical. No anti-inflammatory or tendon-specific role
BPC-157	Broad repair signalling plus the gut application unique to it in this blend	Nothing for skin or collagen. No completed human trial
TB-500	Cell migration and tissue remodelling — a different repair route from BPC-157	No direct research of its own. No skin or inflammation role
KPV	The only anti-inflammatory in the blend, and the only component with no identity ambiguity at all	Does not drive tissue repair or collagen synthesis. No completed human trial

● Component Breakdown

COMPONENT	ROLE IN THE FORMULATION	JULY 2026 PCAC
GHK-Cu	Collagen synthesis, skin remodelling, antioxidant activity	Not reviewed — Feb 2027 track
BPC-157	Broad tissue repair signalling	Recommended 8-6-1
TB-500	Cell migration and tissue repair, inferred from Tβ4	Recommended 8-6-1
KPV	Anti-inflammatory; C-terminal fragment of α-MSH	Recommended 8-6-1

● Practical Considerations

Attribution

With four actives in one vial there is no clean way to tell which component is producing an effect, or which is producing an unwanted one. If isolating a variable matters to you, a single-component preparation answers that question and a four-way blend cannot.

Overlap

KLOW contains both BPC-157 and TB-500, so it overlaps completely with Wolverine and substantially with GLOW. Running KLOW alongside either one compounds those doses rather than broadening coverage. Replacing rather than stacking is the cleaner approach.

THE BOTTOM LINE

The broadest formulation in the range, and the one where the regulatory picture is most split – three components carrying a July 2026 recommendation that FDA has not acted on, and one that has not been reviewed at all. Comprehensive by design, difficult to attribute by consequence.

Research use only. Products referenced in this document are supplied for laboratory and research purposes only and are **not for human or veterinary consumption**, not for diagnostic use, and not for use in food or cosmetics. They are not sold as drugs, dietary supplements or medical devices. **Not medical advice.** This document summarises publicly available research and is provided for informational and educational purposes only. It is not medical advice, not a diagnosis, not a treatment recommendation, and not an offer or promise to treat, cure, mitigate or prevent any disease or condition. Nothing here should be relied upon in place of advice from a qualified, licensed healthcare professional, and you should consult one before making any health decision. **On the statements made here.** Descriptions of research findings summarise what published studies have reported. They are not claims of safety or efficacy, and they should not be read as representing that any outcome will occur. Where research is preclinical (cell or animal), findings may not translate to humans. Individual results vary, and no particular result is promised or implied. Unless expressly stated otherwise, compounds described here are **not approved by the FDA** for any indication. **Regulatory information.** Regulatory positions described are current as of the date of this document and are subject to change without notice; verify current status independently before relying on it. **Buyer responsibility.** Purchasers are responsible for determining the lawfulness of purchase, possession and use in their jurisdiction. **No warranty.** This information is provided “as is” without warranty of any kind, express or implied. To the fullest extent permitted by law, no liability is accepted for any loss or damage arising from reliance on it. **Pricing.** Prices shown are current as of the date of this document, are subject to change without notice, and do not constitute a binding offer. **Sources:** FDA PCAC meeting materials and briefing documents, 23-24 July 2026; Hyman, Phelps & McNamara FDA Law Blog, 24 and 28 July 2026; Mintz, 29 July 2026; Polsinelli, 22 April 2026.